Stay updated on Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial page.

Latest updates to the Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe history now shows a new revision entry (v3.7.0) representing the latest update to the study record. The previous revision (v3.6.6) is no longer listed in the current version history.SummaryDifference0.0%

- Check30 days agoChange DetectedA new revision entry 'Revision: v3.6.6' was added to the history, signaling an update to the record; the previous 'Revision: v3.6.5' entry was noted as removed in the change set.SummaryDifference0.0%

- Check51 days agoChange DetectedThe page shows the revision label updated from v3.6.4 to v3.6.5, indicating a new version of the study history interface.SummaryDifference0.0%

- Check65 days agoChange DetectedThe record history now shows Revision: v3.6.4 instead of v3.6.3. This reflects a recent platform update to the ClinicalTrials.gov release.SummaryDifference0.0%

- Check94 days agoChange DetectedA new site revision entry (v3.6.3) was added to the page history, replacing the previous revision (v3.6.0) and indicating an update to the ClinicalTrials.gov interface.SummaryDifference0.0%

- Check108 days agoChange DetectedA new revision entry (v3.6.0) was added with a note that the study is no longer looking for participants. The previous revision (v3.5.5) was removed.SummaryDifference0.2%

Stay in the know with updates to Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial page.